EGFR and Familial adenomatous polyposis: Furthermore, the EGFR inhibitor erlotinib proved active when combined with the NSAID sulindac in a polyp trial with familial adenomatous polyposis (FAP) patients (Samadder et al., 2016; Samadder et al., 2018).